Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

6(60.0%)

Phase 2

4(40.0%)

10Total

Phase 1(6)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT04925024Phase 2Active Not Recruiting

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Role: lead

NCT04629105Phase 1Active Not Recruiting

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Role: lead

NCT05233774Phase 2Completed

Lomecel-B Effects on Alzheimer's Disease

Role: lead

NCT03525418Phase 1Unknown

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

Role: lead

NCT02587572Phase 2Withdrawn

Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial

Role: lead

NCT02982915Phase 1Completed

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Role: lead

NCT03169231Phase 2Completed

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

Role: lead

NCT02600130Phase 1Completed

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

Role: lead

NCT02398604Phase 1Terminated

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Role: lead

NCT02065245Phase 1Completed

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

Role: lead

All 10 trials loaded